Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy - Cancer Therapy Advisor
Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.
Great Strides in Precision Medicine: Personalized Oncology
Lapatinib and lapatinib plus trastuzumab therapy versus
Lapatinib and lapatinib plus trastuzumab therapy versus
Page 1526 – Cancer Therapy Advisor
Molecules, Free Full-Text
January 2011 - Oncology Practice Digital Network
Risk-based decision-making in the treatment of HER2-positive early
A Phase 1B open-label study of gedatolisib (PF-05212384) in
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies
Page 1597 – Cancer Therapy Advisor
Pharmaceuticals, Free Full-Text